Key Takeaways
- Shares of uniQure plummeted 48% to $20.50 during premarket hours on Tuesday.
- The decline was triggered by disappointing 48-month data from the AMT-130 Huntington’s disease gene therapy trial.
- While AMT-130 demonstrated a 44% reduction in disease progression at the 48-month mark, it failed to achieve statistical significance.
- The company maintains that its FDA submission remains supported by robust 36-month data from all 15 high-dose trial participants.
- A Biologics License Application was filed with the FDA earlier this month through the accelerated approval pathway.
Shares of uniQure experienced a dramatic 48% decline to $20.50 in premarket trading Tuesday morning. The steep selloff followed the Dutch biotechnology firm’s announcement of updated trial results for its experimental Huntington’s disease treatment.
The experimental treatment, designated AMT-130, aims to decelerate the advancement of this deadly neurological condition by reducing concentrations of a harmful protein within the brain.
Data from a 48-month evaluation involving 12 patients receiving the high dose revealed that AMT-130 achieved a 44% reduction in disease advancement. However, this outcome failed to reach the predetermined statistical significance threshold established by researchers.
This represents a significant reversal from June’s optimism, when uniQure announced plans to pursue regulatory clearance for the treatment. Investor enthusiasm at that time drove shares considerably higher.
Breaking Down the Latest Trial Results
Researchers at uniQure evaluated trial participants against an external control cohort. As the study progressed, attrition increased within the external control population.
This attrition resulted in a comparison cohort predominantly consisting of individuals whose condition naturally advanced at a slower rate. According to the company, this compositional shift may have distorted the 48-month analysis.
The biotech firm emphasized an alternative 36-month analysis as offering greater reliability. This assessment encompassed the complete cohort of 15 high-dose recipients and achieved statistical robustness.
An additional 36-month evaluation focusing exclusively on 12 high-dose participants revealed an 80% reduction in disease advancement. These measurements were derived from data gathered through June 30, 2026.
The company also reported that trial participants demonstrated good tolerance to the therapy at both dosage levels examined. Safety concerns were not identified as contributing factors to Tuesday’s share price collapse.
Regulatory Pathway and FDA Engagement
Earlier in the current month, uniQure submitted a Biologics License Application to the Food and Drug Administration. This regulatory filing requested accelerated approval for AMT-130, formally designated as ifezuntirgene inilparvovec.
The application was constructed using the 36-month dataset rather than the more recent 48-month findings. The company stated that FDA officials confirmed during a June consultation that 36-month outcomes from 12 high-dose participants would provide adequate support for the regulatory submission.
The regulatory agency has previously expressed reservations about this therapy. In the prior year, the FDA determined that Phase I and Phase II evidence was insufficient to justify a filing, and as recently as March suggested conducting an additional clinical study.
Huntington’s disease is a hereditary condition with an invariably fatal outcome. No currently approved therapies alter the disease’s progression trajectory; existing treatments only address symptom management.
Development of AMT-130 has spanned almost ten years for uniQure. The therapy represents the cornerstone asset within the company’s research and development portfolio.
In Tuesday’s announcement, uniQure emphasized that the updated information retains significant clinical value for patients considering the absence of alternative disease-modifying therapeutic options. The company intends to share comprehensive findings at an upcoming scientific conference.
Tuesday’s stock collapse is tracking to become uniQure’s steepest single-session percentage loss since November, based on data from Dow Jones Market Data.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
